Integra LifeSciences Holdings Co. (NASDAQ:IART) Given Consensus Rating of "Reduce" by Analysts

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) have earned a consensus rating of "Reduce" from the nine ratings firms that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $27.25.

A number of analysts have recently commented on the stock. BTIG Research raised shares of Integra LifeSciences from a "sell" rating to a "neutral" rating in a research note on Monday, October 7th. Morgan Stanley increased their target price on Integra LifeSciences from $24.00 to $27.00 and gave the company an "underweight" rating in a report on Monday, July 15th. Citigroup lifted their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research note on Tuesday, November 5th. JMP Securities reduced their price objective on Integra LifeSciences from $40.00 to $35.00 and set a "market outperform" rating for the company in a research note on Tuesday, July 30th. Finally, Truist Financial lowered their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a research note on Monday, October 14th.

Institutional Trading of Integra LifeSciences

A number of institutional investors have recently modified their holdings of IART. Texas Permanent School Fund Corp lifted its position in shares of Integra LifeSciences by 1.5% during the 1st quarter. Texas Permanent School Fund Corp now owns 59,524 shares of the life sciences company's stock valued at $2,110,000 after acquiring an additional 870 shares during the period. Concurrent Investment Advisors LLC boosted its position in Integra LifeSciences by 17.3% during the first quarter. Concurrent Investment Advisors LLC now owns 16,943 shares of the life sciences company's stock worth $601,000 after purchasing an additional 2,500 shares in the last quarter. Inspire Investing LLC grew its holdings in Integra LifeSciences by 14.8% in the first quarter. Inspire Investing LLC now owns 10,143 shares of the life sciences company's stock valued at $360,000 after purchasing an additional 1,311 shares during the last quarter. Headlands Technologies LLC increased its position in shares of Integra LifeSciences by 54.3% in the first quarter. Headlands Technologies LLC now owns 4,764 shares of the life sciences company's stock valued at $169,000 after buying an additional 1,677 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in shares of Integra LifeSciences by 8.0% during the 1st quarter. Russell Investments Group Ltd. now owns 50,502 shares of the life sciences company's stock worth $1,790,000 after buying an additional 3,743 shares during the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART traded down $0.41 during midday trading on Tuesday, reaching $25.04. 129,819 shares of the stock were exchanged, compared to its average volume of 1,098,022. The company has a quick ratio of 2.10, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The firm has a 50-day simple moving average of $19.18 and a two-hundred day simple moving average of $24.29. Integra LifeSciences has a twelve month low of $16.81 and a twelve month high of $45.42. The firm has a market cap of $1.93 billion, a price-to-earnings ratio of -282.78, a PEG ratio of 0.84 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $380.80 million for the quarter, compared to analyst estimates of $375.81 million. During the same period last year, the company earned $0.76 earnings per share. Integra LifeSciences's quarterly revenue was down .4% compared to the same quarter last year. As a group, analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.